Ligand Pharmaceuticals Incorporated (NASDAQ:LGND – Get Free Report)’s share price passed below its 50-day moving average during trading on Monday following insider selling activity. The stock has a 50-day moving average of $302.03 and traded as low as $300.55. Ligand Pharmaceuticals shares last traded at $301.71, with a volume of 187,061 shares changing hands.
Specifically, Director Martine Zimmermann sold 2,000 shares of the company’s stock in a transaction on Thursday, November 12th. The shares were sold at an average price of $318.17, for a total value of $636,340.00. Following the completion of the transaction, the director directly owned 1,782 shares in the company, valued at approximately $566,978.94. This represents a 52.88% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director John Kozarich sold 500 shares of the firm’s stock in a transaction dated Thursday, November 12th. The stock was sold at an average price of $325.00, for a total transaction of $162,500.00. Following the completion of the sale, the director directly owned 42,122 shares of the company’s stock, valued at approximately $13,689,650. This represents a 1.17% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In other news, Director Jason Aryeh sold 3,000 shares of Ligand Pharmaceuticals stock in a transaction dated Tuesday, November 10th. The shares were sold at an average price of $320.05, for a total transaction of $960,150.00. Following the sale, the director owned 105,476 shares of the company’s stock, valued at approximately $33,757,593.80. The trade was a 2.77% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink.
Analyst Ratings Changes
Several equities analysts recently issued reports on LGND shares. Citigroup boosted their price target on shares of Ligand Pharmaceuticals from $397.00 to $402.00 and gave the company a “buy” rating in a research report on Thursday, November 5th. HC Wainwright restated a “buy” rating and issued a $358.00 price objective on shares of Ligand Pharmaceuticals in a report on Thursday, September 24th. Weiss Ratings cut Ligand Pharmaceuticals from a “buy (b)” rating to a “hold (c)” rating in a research report on Monday, November 2nd. Barclays lifted their price objective on Ligand Pharmaceuticals from $345.00 to $350.00 and gave the company an “overweight” rating in a research report on Wednesday, November 11th. Finally, Leerink Partners began coverage on Ligand Pharmaceuticals in a report on Friday, August 14th. They set an “outperform” rating and a $330.00 target price on the stock. Eight investment analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $355.38.
View Our Latest Research Report on Ligand Pharmaceuticals
Ligand Pharmaceuticals Trading Down 2.3%
The stock’s fifty day simple moving average is $302.03 and its two-hundred day simple moving average is $258.58. The firm has a market cap of $6.03 billion, a PE ratio of 134.69, a PEG ratio of 5.52 and a beta of 1.16. The company has a quick ratio of 1.19, a current ratio of 1.22 and a debt-to-equity ratio of 0.71.
Ligand Pharmaceuticals (NASDAQ:LGND – Get Free Report) last released its earnings results on Thursday, October 29th. The biotechnology company reported $2.67 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.33 by $0.34. Ligand Pharmaceuticals had a net margin of 20.27% and a return on equity of 5.22%. The firm had revenue of $78.75 million during the quarter, compared to analyst estimates of $77.00 million. During the same period last year, the business earned $3.09 earnings per share. The business’s revenue was down 31.8% on a year-over-year basis. On average, sell-side analysts forecast that Ligand Pharmaceuticals Incorporated will post 2.35 EPS for the current fiscal year.
Institutional Inflows and Outflows
A number of institutional investors and hedge funds have recently added to or reduced their stakes in the stock. VIRGINIA RETIREMENT SYSTEMS ET Al purchased a new stake in shares of Ligand Pharmaceuticals in the second quarter worth $1,359,000. Squarepoint Ops LLC increased its holdings in shares of Ligand Pharmaceuticals by 256.6% during the second quarter. Squarepoint Ops LLC now owns 22,800 shares of the biotechnology company’s stock valued at $7,207,000 after acquiring an additional 16,406 shares in the last quarter. JW Asset Management LLC purchased a new position in shares of Ligand Pharmaceuticals in the 2nd quarter worth about $1,264,000. Hsbc Holdings PLC purchased a new position in shares of Ligand Pharmaceuticals in the 1st quarter worth about $690,000. Finally, Bank of America Corp DE raised its position in shares of Ligand Pharmaceuticals by 31.4% in the 1st quarter. Bank of America Corp DE now owns 157,865 shares of the biotechnology company’s stock worth $31,518,000 after purchasing an additional 37,696 shares during the last quarter. Institutional investors own 91.28% of the company’s stock.
About Ligand Pharmaceuticals
Ligand Pharmaceuticals is a biopharmaceutical company that works with pharmaceutical and biotechnology partners to develop and commercialize medicines. Rather than focusing primarily on selling drugs directly, Ligand licenses technologies and drug-development assets and may receive royalties and other payments from partner programs. Its technologies include Captisol, a formulation platform designed to improve the solubility and delivery of certain medicines. Ligand also holds economic interests in a portfolio of partnered products and drug candidates across multiple therapeutic areas.
See Also
- Five stocks we like better than Ligand Pharmaceuticals
- Ondas Is Building a Defense Growth Engine, But Can It Deliver on Its Backlog?
- Orbiting Growth: Federal Contracts Boost Viasat’s Outlook
- Modine Manufacturing Scales Up to Solve the AI Heat Problem
- Nebius Revenue Is Surging, But Its Spending Is Raising Bigger Questions
Receive News & Ratings for Ligand Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ligand Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
